The Antidote: Taking a Look at “Pharmerging” Markets and the Resurgence in UK Biotech IPOs
Add bookmarkPharma IQ is proud to bring you the latest edition of The Antidote, the quarterly lifesciences newsletter from Europe’s largest law firm, CMS. This edition focuses on the increasing opportunities in Asia, and the resurgence of the UK biotech IPO.
By CMS
|
Have Your Say Rate this feature and give us your feedback in the comments section below |